A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal

What Was Tested

This randomized controlled trial paper looks at Pancreatic Polypeptide and Cholecystokinin (CCK).

Standard medical therapy for patients with acromegaly includes somatostatin analogs.

Area under the curve and peak responses were analyzed using one-way repeated-measures ANOVA (on ranks where appropriate).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, men only.

Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The participants were allocated by chance, so the Pancreatic Polypeptide group and the comparison group should start out alike.

Being open-label, the Pancreatic Polypeptide study did not mask who received what.

In the crossover set-up each of the participants took both Pancreatic Polypeptide and the comparison in turn, acting as their own control.

What Was Measured

Area under the curve and peak responses were analyzed using one-way repeated-measures ANOVA (on ranks where appropriate).

Topics PubMed links to this paper include Blood Glucose, Cholecystokinin, Eating, Food, Glucose, Glucose Tolerance Test and Hormones.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Pancreatic Polypeptide and Cholecystokinin (CCK).

The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Pancreatic Polypeptide compound page and the Cholecystokinin (CCK) compound page, all human trials.